answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body responsible for providing guidance on the prevention and treatment of ill health
and the promotion of good health and social care for the National Health Service.
NICE has provided recommendations on the use of tamoxifen in pre and postmenopausal
women in its clinical guideline on ‘Early and locally advanced breast cancer: diagnosis
and treatment’ which is currently being updated. The guideline can be found at:</p><p>
</p><p><a href="https://www.nice.org.uk/guidance/cg80/chapter/1-Guidance#endocrine-therapy"
target="_blank">https://www.nice.org.uk/guidance/cg80/chapter/1-Guidance#endocrine-therapy</a></p><p>
</p><p>NICE is currently updating the guideline, including its recommendations on
the use of tamoxifen, and published draft updated guidance for consultation on 24
January.</p>
|
|